IONS250117C40000
- 0.03
- 0.000.00%
Ionis Pharmaceuticals Newsroom
Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities
Ionis to Present at 43rd Annual J.P. Morgan Healthcare Conference
Denali Therapeutics' Amyotrophic Lateral Sclerosis Misses Pivotal Trial, But Analyst Says It Was Expected
Bernstein Maintains Ionis Pharmaceuticals(IONS.US) With Hold Rating, Cuts Target Price to $51
Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic
Insider Trades: Walmart, Teva Among Notable Names This Week
Are Investors Undervaluing Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) By 31%?
Insider Purchase: Director at $IONS (IONS) Buys 2,500 Shares
Analysts Offer Insights on Healthcare Companies: 60 Degrees Pharmaceuticals, Inc. (SXTP), Ionis Pharmaceuticals (IONS) and Zura Bio (ZURA)
PANTHERx Rare Selected by Ionis as Specialty Pharmacy for TRYNGOLZA (Olezarsen)
Piper Sandler Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Maintains Target Price $62
Barclays Maintains Ionis Pharmaceuticals(IONS.US) With Hold Rating, Maintains Target Price $51
Analysts Conflicted on These Healthcare Names: Ionis Pharmaceuticals (IONS) and UnitedHealth (UNH)
Express News | Ionis Pharmaceuticals Inc : Oppenheimer Raises Target Price to $78 From $75
A Quick Look at Today's Ratings for Ionis Pharmaceuticals(IONS.US), With a Forecast Between $59 to $67
Sector Update: Health Care Stocks Mixed Premarket Friday
The Analyst Verdict: Ionis Pharmaceuticals In The Eyes Of 6 Experts
Express News | Needham Maintains Buy on Ionis Pharmaceuticals, Maintains $60 Price Target
Ionis Pharmaceuticals Analyst Ratings
Ionis Pharmaceuticals Reports FDA Approval of Tryngolza